Evenity (Romosozumab) for Osteoporosis: Dual-Action Bone Building

Evenity (romosozumab-aqqg) is a humanized monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that suppresses bone formation. It is the only osteoporosis medication with a dual anabolic and antiresorptive effect.

Mechanism of Action

  1. Sclerostin inhibition: Romosozumab binds sclerostin → prevents Wnt pathway antagonism → unleashes osteoblast activity.
  2. Anabolic effect: Marked increase in bone formation (P1NP ↑ 3–5×), new bone deposition on trabecular and cortical surfaces.
  3. Antiresorptive effect: Concurrent reduction in bone resorption markers (CTX ↓ 50–60%) via osteoprotegerin/RANKL modulation.
  4. Net result: Rapid, substantial gains in BMD (spine +13–15%, hip +5–6% at 12 months) and improved bone geometry/strength.

Indication & Patient Selection

  • Postmenopausal women with osteoporosis at high fracture risk (prior osteoporotic fracture, multiple risk factors, T-score ≤–2.5 with FRAX high risk).
  • Men with osteoporosis at high fracture risk.
  • Patients who have failed or are intolerant to other therapies.
  • Treatment duration: 12 monthly doses only (lifetime max).

Key Trial Data (FRAME, ARCH, STRUCTURE)

  • FRAME: vs. placebo → 73% ↓ new vertebral fractures, 36% ↓ clinical fractures at 12 mo.
  • ARCH: vs. alendronate → 48% ↓ new vertebral, 27% ↓ non-vertebral, 45% ↓ hip fractures at 24 mo (12 mo romosozumab → alendronate).
  • STRUCTURE: Superior BMD gains vs. teriparatide at 12 mo.

Administration

  • 210 mg SC monthly (two 105 mg/1.17 mL injections) × 12 doses.
  • Administered by healthcare professional.
  • Calcium 1000–1200 mg/day + vitamin D 800–1000 IU/day required.

Safety Considerations

  • Cardiovascular: ARCH showed ↑ MACE (2.5% vs. 1.9% alendronate). Contraindicated if MI/stroke within 1 year. Assess CV risk before starting.
  • Hypocalcemia: Correct pre-existing; monitor.
  • ONJ & atypical femoral fracture: Rare; similar to other antiresorptives.
  • Injection-site reactions, arthralgia, headache.

Monitoring

  • Baseline: CV risk assessment, calcium, 25-OH vitamin D, eGFR.
  • Follow-up: Calcium, clinical fracture assessment.
  • BMD at 12 months (end of treatment).

Sequencing Strategy

After 12 months of Evenity, transition to an antiresorptive (bisphosphonate or denosumab) to consolidate gains. This anabolic-to-antiresorptive sequence is the standard of care.

Evenity offers unparalleled bone-building speed and magnitude for high-risk patients, with a defined treatment window and mandatory antiresorptive follow-up.

Osteoporosis - Related Articles